Pharmaceutical

Antengene and Hansoh partner to commercialise XPOVIO in China

Antengene has signed a collaboration agreement with Hansoh Pharma to commercialise XPOVIO (selinexor) in mainland China.

Aug 12, 2023 - 20:00
Antengene and Hansoh partner to commercialise XPOVIO in China
Antengene has signed a collaboration agreement with Hansoh Pharma to commercialise XPOVIO (selinexor) in mainland China.
Read the original article

Tags:

Previous Article

Absci and Caltech receive grant to develop HIV therapeutic vaccine

Next Article

FDA accepts Astellas’ sNDA for CRESEMBA to treat fungal infections

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Johnson & Johnson gets grant for heart ultrasound image...

Apr 25, 2024

South Korea seeks to accelerate drug reimbursement administration process

South Korea seeks to accelerate drug reimbursement admi...

Jun 22, 2024

Travere Therapeutics drug, approved for one rare and deadly kidney disease, fails in study of another

Travere Therapeutics drug, approved for one rare and de...

May 1, 2023